patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_997619 | REC_0003901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.2 | 65 | male | 0 | 13 | 3.4 | 4 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:57.809891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132540 | REC_0003902 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 2.5 | 61 | male | 1 | 47 | 5.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:35:57.810127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855064 | REC_0003903 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 7.3 | 79 | female | 1 | 16 | 5.2 | 0 | alectinib 600 mg BID | 13.1 | false | MSS | 2026-03-15T05:35:57.810356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853952 | REC_0003904 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.3 | 61 | male | 1 | 43 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:35:57.810587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370682 | REC_0003905 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 4.7 | 60 | male | 0 | 21 | 5.8 | 5 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:57.810818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767102 | REC_0003906 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.8 | 83 | female | 2 | 83 | 5.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.5 | true | MSS | 2026-03-15T05:35:57.811045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882296 | REC_0003907 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14 | 76 | female | 3 | 13 | 5 | 2 | entrectinib 600 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:57.811275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986888 | REC_0003908 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.4 | 81 | female | 1 | 15 | 6.6 | 8 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:57.811507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522834 | REC_0003909 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 14.4 | 69 | female | 0 | 10 | 5.1 | 3 | alectinib 600 mg BID | 10.1 | false | MSI-H | 2026-03-15T05:35:57.811736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574702 | REC_0003910 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 58 | female | 0 | 17 | 6.4 | 6 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:57.811966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763299 | REC_0003911 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 7 | 71 | female | 1 | 4 | 5.3 | 1 | osimertinib 80 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:57.812240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737662 | REC_0003912 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 11.7 | 76 | female | 2 | 9 | 7.7 | 2 | pembrolizumab 200 mg q3w | 24.5 | false | MSS | 2026-03-15T05:35:57.812480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690438 | REC_0003913 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.4 | 74 | female | 2 | 25 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:57.812719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819771 | REC_0003914 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.6 | 75 | female | 3 | 16 | 4 | 5 | entrectinib 600 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:57.813009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205246 | REC_0003915 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.2 | 72 | female | 2 | 18 | 4.9 | 5 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:57.813248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860202 | REC_0003916 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.2 | 66 | female | 1 | 19 | 7.8 | 3 | osimertinib 80 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:35:57.813480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850712 | REC_0003917 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 8.2 | 77 | male | 2 | 14 | 7 | 2 | pembrolizumab 200 mg q3w | 31.4 | false | MSS | 2026-03-15T05:35:57.813713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638719 | REC_0003918 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 13.1 | 63 | male | 1 | 19 | 5.6 | 2 | osimertinib 80 mg daily | 21.9 | true | MSI-H | 2026-03-15T05:35:57.813948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468628 | REC_0003919 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 15.8 | 64 | male | 0 | 19 | 6.3 | 7 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:35:57.814182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375003 | REC_0003920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 16.9 | 52 | male | 0 | 18 | 5.6 | 9 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.814415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202448 | REC_0003921 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 11.9 | 54 | female | 0 | 19 | 2.9 | 6 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.814648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683146 | REC_0003922 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.4 | 57 | male | 0 | 42 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.8 | false | MSS | 2026-03-15T05:35:57.814880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991580 | REC_0003923 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 14.7 | 65 | female | 1 | 8 | 3.9 | 3 | osimertinib 80 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:57.815117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287848 | REC_0003924 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.7 | 90 | female | 1 | 8 | 8 | 0 | alectinib 600 mg BID | 18.6 | false | MSI-H | 2026-03-15T05:35:57.815346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901198 | REC_0003925 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.9 | 64 | female | 1 | 51 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:57.815576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117207 | REC_0003926 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.8 | 76 | female | 1 | 57 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:57.815804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720255 | REC_0003927 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.3 | 75 | female | 1 | 34 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.8 | true | MSS | 2026-03-15T05:35:57.816202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109526 | REC_0003928 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 18.2 | 65 | male | 1 | 28 | 5.6 | 6 | osimertinib 80 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:35:57.816456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260956 | REC_0003929 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.8 | 74 | female | 2 | 17 | 5.9 | 7 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:57.816689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807805 | REC_0003930 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.4 | 53 | male | 0 | 15 | 4.4 | 6 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:57.816923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393524 | REC_0003931 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 17 | 14.2 | 62 | female | 0 | 13 | 4 | 0 | osimertinib 80 mg daily | 38.5 | false | MSS | 2026-03-15T05:35:57.817158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991198 | REC_0003932 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.1 | 74 | male | 2 | 23 | 5.9 | 7 | osimertinib 80 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:35:57.817394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802043 | REC_0003933 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 19.4 | 62 | male | 1 | 12 | 4.4 | 6 | sotorasib 960 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:35:57.817632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753896 | REC_0003934 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 27 | 8.4 | 59 | female | 1 | 14 | 5.1 | 0 | pembrolizumab 200 mg q3w | 27 | true | MSS | 2026-03-15T05:35:57.817865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466699 | REC_0003935 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 9.3 | 79 | male | 1 | 48 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:35:57.818104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114787 | REC_0003936 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 4.6 | 72 | female | 1 | 17 | 3.8 | 2 | pembrolizumab 200 mg q3w | 18.1 | true | MSS | 2026-03-15T05:35:57.818352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349997 | REC_0003937 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.9 | 64 | male | 0 | 12 | 3.9 | 2 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.818604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382431 | REC_0003938 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.9 | 58 | male | 0 | 27 | 6.5 | 5 | osimertinib 80 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:57.818856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824061 | REC_0003939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 11.6 | 70 | female | 1 | 16 | 7.3 | 5 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:57.819137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406193 | REC_0003940 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 7.3 | 57 | male | 0 | 1 | 4.6 | 5 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.819514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929256 | REC_0003941 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.9 | 62 | male | 1 | 12 | 3.2 | 1 | pembrolizumab 200 mg q3w | 27 | false | MSS | 2026-03-15T05:35:57.819780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872839 | REC_0003942 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.8 | 66 | female | 0 | 20 | 5.7 | 6 | entrectinib 600 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:57.820032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498687 | REC_0003943 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.2 | 57 | female | 1 | 91 | 5.2 | 2 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:57.820359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749825 | REC_0003944 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.8 | 59 | female | 0 | 3 | 4.2 | 6 | sotorasib 960 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:57.820623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608549 | REC_0003945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.4 | 67 | female | 0 | 36 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.8 | false | MSS | 2026-03-15T05:35:57.820877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479071 | REC_0003946 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.6 | 62 | male | 0 | 18 | 4.7 | 5 | osimertinib 80 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:35:57.821138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836502 | REC_0003947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.1 | 56 | female | 0 | 19 | 4.5 | 4 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.821388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456713 | REC_0003948 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 16.5 | 55 | male | 1 | 10 | 5 | 5 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:57.821642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427252 | REC_0003949 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.2 | 66 | female | 0 | 40 | 5 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.2 | true | MSS | 2026-03-15T05:35:57.821886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928891 | REC_0003950 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.1 | 61 | female | 0 | 18 | 8 | 4 | sotorasib 960 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:57.822129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950562 | REC_0003951 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 16.5 | 70 | female | 1 | 11 | 5.8 | 2 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.822366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552724 | REC_0003952 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.1 | 68 | male | 0 | 22 | 6 | 6 | osimertinib 80 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.822604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929862 | REC_0003953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 16.1 | 67 | female | 1 | 11 | 4.5 | 6 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.822982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611741 | REC_0003954 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 13.5 | 65 | female | 0 | 18 | 6.7 | 2 | pembrolizumab 200 mg q3w | 14 | false | MSI-H | 2026-03-15T05:35:57.823226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784073 | REC_0003955 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 17 | 18.8 | 58 | male | 0 | 14 | 6.7 | 0 | osimertinib 80 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:57.823463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111645 | REC_0003956 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14 | 68 | female | 0 | 18 | 4.8 | 4 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:57.823697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943173 | REC_0003957 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 6 | 76 | female | 1 | 49 | 6.4 | 1 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.823937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894501 | REC_0003958 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10 | 75 | male | 1 | 20 | 5.9 | 1 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:57.824259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629996 | REC_0003959 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.3 | 76 | female | 3 | 22 | 5.8 | 6 | entrectinib 600 mg daily | 18.8 | true | MSS | 2026-03-15T05:35:57.824496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510472 | REC_0003960 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 17.6 | 63 | female | 1 | 16 | 5.7 | 2 | sotorasib 960 mg daily | 19.5 | true | MSI-H | 2026-03-15T05:35:57.824736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969231 | REC_0003961 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.6 | 78 | female | 3 | 0 | 7.4 | 6 | sotorasib 960 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:57.824971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103114 | REC_0003962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 7.1 | 72 | female | 2 | 14 | 6.3 | 5 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:57.825202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420836 | REC_0003963 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.7 | 59 | male | 0 | 20 | 7.5 | 9 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.825437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839716 | REC_0003964 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 16.2 | 72 | female | 1 | 11 | 6.3 | 5 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:57.825671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392108 | REC_0003965 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 7.3 | 62 | male | 1 | 13 | 4.5 | 1 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:57.825903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786611 | REC_0003966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.5 | 62 | female | 1 | 4 | 5.9 | 6 | alectinib 600 mg BID | 9.4 | true | MSS | 2026-03-15T05:35:57.826209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909872 | REC_0003967 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 4.4 | 68 | female | 1 | 16 | 6.2 | 2 | entrectinib 600 mg daily | 29.1 | false | MSS | 2026-03-15T05:35:57.826443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700537 | REC_0003968 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 10.8 | 66 | female | 0 | 17 | 4.1 | 2 | sotorasib 960 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:57.826675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727146 | REC_0003969 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 9.1 | 64 | male | 0 | 7 | 6.7 | 2 | entrectinib 600 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.826908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758887 | REC_0003970 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 17.1 | 69 | female | 0 | 5 | 6.2 | 6 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:57.827139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305167 | REC_0003971 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 6.7 | 73 | female | 2 | 11 | 6.5 | 1 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:57.827367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621608 | REC_0003972 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.6 | 72 | female | 2 | 14 | 7.3 | 2 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:57.827596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887977 | REC_0003973 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 15.6 | 89 | female | 2 | 19 | 6.3 | 2 | osimertinib 80 mg daily | 24.2 | false | MSI-H | 2026-03-15T05:35:57.827825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423985 | REC_0003974 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 14.9 | 64 | male | 0 | 23 | 4.2 | 2 | entrectinib 600 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.828061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772273 | REC_0003975 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8.7 | 67 | female | 1 | 12 | 6.7 | 8 | entrectinib 600 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.828328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974530 | REC_0003976 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9 | 85 | female | 0 | 10 | 3 | 3 | entrectinib 600 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.828556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957660 | REC_0003977 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 10.5 | 58 | male | 1 | 7 | 6.3 | 5 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.828789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704673 | REC_0003978 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 14.2 | 80 | female | 1 | 12 | 2 | 1 | entrectinib 600 mg daily | 30.4 | false | MSS | 2026-03-15T05:35:57.829024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288878 | REC_0003979 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.4 | 73 | male | 2 | 6 | 4.2 | 1 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.829302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793802 | REC_0003980 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 12.8 | 51 | female | 0 | 9 | 4.5 | 0 | osimertinib 80 mg daily | 22.4 | true | MSI-H | 2026-03-15T05:35:57.829541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598411 | REC_0003981 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.7 | 63 | male | 0 | 12 | 4.7 | 2 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:57.829775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381154 | REC_0003982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 4.2 | 76 | female | 2 | 22 | 5.5 | 6 | entrectinib 600 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.830003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840505 | REC_0003983 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.2 | 63 | female | 1 | 21 | 7.3 | 4 | sotorasib 960 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.830237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316275 | REC_0003984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.4 | 48 | female | 0 | 0 | 6.2 | 4 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.830471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876338 | REC_0003985 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 13.6 | 70 | female | 1 | 4 | 5.8 | 5 | pembrolizumab 200 mg q3w | 10.6 | false | MSI-H | 2026-03-15T05:35:57.830706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913610 | REC_0003986 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 8.8 | 66 | male | 0 | 14 | 7.7 | 1 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:57.830938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692793 | REC_0003987 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.7 | 77 | female | 1 | 75 | 3.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:57.831170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246766 | REC_0003988 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.3 | 67 | male | 0 | 11 | 4.5 | 6 | osimertinib 80 mg daily | 5.7 | true | MSS | 2026-03-15T05:35:57.831404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715579 | REC_0003989 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.6 | 65 | male | 0 | 72 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:35:57.831635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684966 | REC_0003990 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 11.1 | 85 | female | 2 | 6 | 7.2 | 1 | alectinib 600 mg BID | 22.5 | true | MSS | 2026-03-15T05:35:57.831863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732856 | REC_0003991 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.1 | 73 | female | 2 | 5 | 5.2 | 2 | entrectinib 600 mg daily | 23.6 | false | MSS | 2026-03-15T05:35:57.832137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993011 | REC_0003992 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.1 | 66 | male | 0 | 17 | 5.4 | 6 | entrectinib 600 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:57.832429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165217 | REC_0003993 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 2.2 | 77 | male | 2 | 18 | 4.3 | 0 | pembrolizumab 200 mg q3w | 27.8 | false | MSS | 2026-03-15T05:35:57.832673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109077 | REC_0003994 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.8 | 71 | female | 1 | 23 | 5 | 2 | sotorasib 960 mg daily | 5.9 | false | MSS | 2026-03-15T05:35:57.832909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679089 | REC_0003995 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 9.6 | 81 | female | 2 | 24 | 5.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:57.833137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277201 | REC_0003996 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 19.6 | 84 | female | 2 | 14 | 4.5 | 1 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:57.833375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990752 | REC_0003997 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13 | 71 | female | 2 | 15 | 5.1 | 8 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:57.833607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296419 | REC_0003998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.4 | 70 | female | 2 | 25 | 6.8 | 4 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:57.833836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463110 | REC_0003999 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 9.4 | 77 | female | 3 | 9 | 3.5 | 8 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:57.834068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567651 | REC_0004000 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.2 | 68 | female | 1 | 8 | 4.6 | 1 | sotorasib 960 mg daily | 27.7 | true | MSS | 2026-03-15T05:35:57.834299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.